211 related articles for article (PubMed ID: 28544691)
1. Damned if you do, damned if you don't: The evolving story of de novo and recurrent hepatocellular carcinoma amongst those treated with direct-acting antivirals for hepatitis C virus.
Yang JD; Leise MD
Liver Int; 2017 Jun; 37(6):809-811. PubMed ID: 28544691
[No Abstract] [Full Text] [Related]
2. Hepatocellular carcinoma and direct-acting antivirals: A never ending story?
Calvaruso V; Craxì A
Liver Int; 2017 Jun; 37(6):812-814. PubMed ID: 28544693
[No Abstract] [Full Text] [Related]
3. Con: Treating hepatitis C virus With direct-acting antivirals: Fear not the perceived threat of hepatocellular carcinoma.
Mehta N; Yao FY
Liver Transpl; 2017 Dec; 23(12):1596-1600. PubMed ID: 29024442
[No Abstract] [Full Text] [Related]
4. De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus.
Abdelaziz AO; Nabil MM; Abdelmaksoud AH; Shousha HI; Cordie AA; Hassan EM; Omran DA; Leithy R; Elbaz TM
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):39-43. PubMed ID: 29064851
[TBL] [Abstract][Full Text] [Related]
5. Pro: Direct-acting antivirals are associated with occurrence and recurrence of hepatocellular carcinoma.
Trotter JF
Liver Transpl; 2017 Dec; 23(12):1593-1595. PubMed ID: 29024516
[No Abstract] [Full Text] [Related]
6. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
[TBL] [Abstract][Full Text] [Related]
7. Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis.
Stournaras E; Neokosmidis G; Stogiannou D; Protopapas A; Tziomalos K
Eur J Gastroenterol Hepatol; 2018 Nov; 30(11):1277-1282. PubMed ID: 30179906
[TBL] [Abstract][Full Text] [Related]
8. Impact of Hepatitis C Virus Infection on Hepatocellular Carcinoma.
Tholey DM; Ahn J
Gastroenterol Clin North Am; 2015 Dec; 44(4):761-73. PubMed ID: 26600218
[TBL] [Abstract][Full Text] [Related]
9. De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era.
Kwong AJ; Kim WR; Flemming JA
Hepatology; 2018 Oct; 68(4):1288-1297. PubMed ID: 29672886
[TBL] [Abstract][Full Text] [Related]
10. Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals: comparative analysis with non-direct-acting antivirals-treated patients.
Abdelaziz AO; Nabil MM; Abdelmaksoud AH; Shousha HI; Hashem MB; Hassan EM; Salah A; Omran DA; Elbaz TM
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):75-79. PubMed ID: 30199473
[TBL] [Abstract][Full Text] [Related]
11. Management of recurrent hepatitis C virus after liver transplantation.
Jiménez-Pérez M; González-Grande R; Rando-Muñoz FJ
World J Gastroenterol; 2014 Nov; 20(44):16409-17. PubMed ID: 25469009
[TBL] [Abstract][Full Text] [Related]
12. Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: Comparison with pegylated interferon-based therapy in chronic hepatitis C patients.
Yoo SH; Kwon JH; Nam SW; Kim HY; Kim CW; You CR; Choi SW; Cho SH; Han JY; Song DS; Chang UI; Yang JM; Lee HL; Lee SW; Han NI; Kim SH; Song MJ; Hwang S; Sung PS; Jang JW; Bae SH; Choi JY; Yoon SK
J Viral Hepat; 2018 Oct; 25(10):1189-1196. PubMed ID: 29660199
[TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy.
Villani R; Vendemiale G; Serviddio G
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30583555
[TBL] [Abstract][Full Text] [Related]
14. The socioeconomic impact of hepatitis C infection and liver transplantation in Mexico.
Méndez-Sánchez N
Ann Hepatol; 2012; 11(4):550-1. PubMed ID: 22700637
[No Abstract] [Full Text] [Related]
15. Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?
Cabibbo G; Celsa C; Cammà C; Craxì A
Liver Int; 2018 Dec; 38(12):2108-2116. PubMed ID: 29935096
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular Carcinoma Occurrence/Recurrence after Direct-Acting Antivirals for Hepatitis C in Egyptian Cohort: Single-Center Experience.
Lashen SA; Shamseya MM; Madkour MA
Dig Dis; 2019; 37(6):488-497. PubMed ID: 31216532
[TBL] [Abstract][Full Text] [Related]
17. Rapidly growing hepatocellular carcinoma recurrence during direct-acting antiviral treatment for chronic hepatitis C.
Yamashita N; Tanimoto H; Shimoda S; Komori A; Nomura H
Clin J Gastroenterol; 2018 Dec; 11(6):497-500. PubMed ID: 29948818
[TBL] [Abstract][Full Text] [Related]
18. Editorial - HCC in HCV patients and the direct acting antivirals: is there really a link?
Marrone A; Franci G; Perrella A; Nevola R; Chianese A; Adinolfi LE; Sasso FC; Rinaldi L
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):983-987. PubMed ID: 32017007
[No Abstract] [Full Text] [Related]
19. Immunoglobulin G4-associated de novo autoimmune hepatitis after liver transplantation for chronic hepatitis B- and C-related cirrhosis and hepatocellular carcinoma: a case report with literature review.
Zhao XY; Rakhda MI; Wang TI; Jia JD
Transplant Proc; 2013 Mar; 45(2):824-7. PubMed ID: 23498828
[TBL] [Abstract][Full Text] [Related]
20. [Hepatitis C-related hepatocellular carcinoma and the treatment with direct-acting antiviral agents].
Liu X; Gao YH; Niu JQ
Zhonghua Gan Zang Bing Za Zhi; 2017 Dec; 25(12):944-947. PubMed ID: 29325299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
